ReviewJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026
Exploring the association of electrocardiographic markers and arrhythmic risk in hypertrophic cardiomyopathy: A systematic review and meta-analysis.
Review in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is a primary genetic myocardial disorder associated with sudden cardiac death (SCD) due to ventricular arrhythmias, however risk stratification remains challenging. Electrocardiographic (ECG) markers may offer non-invasive tools for improved risk assessment, but their prognostic value remains unclear. The purpose of this study is to systematically evaluate the association between ECG markers and the risk of major arrhythmic events (MAEs) in HCM patients.
methodsWe conducted a systematic search of PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) and Clinical Trials from inception to December 2024, including studies providing data on ECG variables and MAEs in patients with HCM. Pooled effect estimates were calculated using Der Simonian-Laird random-effects model.
results12 studies with 3,419 HCM patients were included. Pooled results demonstrated that the presence of fragmented QRS (fQRS) was significantly associated with MAEs (OR: 7.03, 95% CI: 3.19; 15.48) with moderate diagnostic performance [AUC = 0.76, sensitivity 59% (95% CI: 37%; 78%), specificity 80% (95% CI: 64%; 90%)]. Prolonged QTc interval (MD: 10.57 ms, 95% CI: 1-20.15), T-wave peak-to-end (Tp-e) interval (MD: 15.35 ms, 95% CI: 9.45; 21.26) and QT dispersion (QTd) (SMD: 0.48; 95% CI: 0.19; 0.77) were also associated with MAEs. In contrast, PR interval, P-wave, QRS duration and the presence of right bundle branch block (RBBB) demonstrated no significant associations.
conclusionThis meta-analysis highlights the potential prognostic utility of specific ECG markers, particularly fQRS and repolarization abnormalities in stratifying arrhythmic risk in HCM. PROSPERO REGISTRATION NUMBER: CRD42025635276.
Indexed as
Identifiers
41538113What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.